[{"data":1,"prerenderedAt":145},["ShallowReactive",2],{"drug-agomelatine":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":35,"contraindications":58,"warnings":68,"renal":76,"monitoring":77,"interactions":78,"review":79,"examples":82,"atc":88,"iran":90,"links":102,"populations":112},"agomelatine",1,{"fa":7,"en":8},"آگوملاتین","Agomelatine","nervous-system",{"fa":11,"en":12},"آگونیست ملاتونین و آنتاگونیست 5-HT2C","Melatonergic agonist and 5-HT2C antagonist",[14],{"name":15,"market":16},"Valdoxan","UK",[18,19,7],"valdoxan","والدوکسان",[21],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"tab-25","tablet","oral","25 mg film-coated tablet",{"amount":27,"unit":28,"perUnit":23,"scored":29},25,"mg",false,[16],[32],{"source":33,"section":34},"emc-valdoxan","6.5",[36],{"id":37,"disease":37,"label":38,"population":41,"type":45,"unit":28,"dose":46,"refs":48,"notes":51},"mdd",{"fa":39,"en":40},"افسردگی اساسی بزرگسال — ۲۵ mg هنگام خواب؛ پس از ۲ هفته بدون بهبود تا ۵۰ mg","Adult major depression — 25 mg at bedtime; 50 mg if no improvement after 2 weeks",{"minAge":42},{"value":43,"unit":44},18,"year","fixed",{"perDose":27,"perDoseMax":47,"dosesPerDay":5},50,[49],{"source":33,"section":50},"4.2",[52],{"text":53,"refs":56},{"fa":54,"en":55},"آزمایش کبد پیش از شروع و حدود ۳، ۶، ۱۲ و ۲۴ هفته؛ ترانس‌آمیناز بالای ۳ برابر: شروع نشود و قطع شود. افزایش به ۵۰ mg با پایش دقیق کبد.","Liver tests before starting and at about 3, 6, 12 and 24 weeks; do not start (and stop) if transaminases exceed 3× ULN. Increase to 50 mg only with strict liver monitoring.",[57],{"source":33,"section":50},[59],{"id":60,"severity":61,"text":62,"refs":65},"ci","block",{"fa":63,"en":64},"نارسایی کبد (سیروز یا بیماری فعال کبد) یا ترانس‌آمیناز بالای ۳ برابر؛ مهارکننده قوی CYP1A2 (فلووکسامین، سیپروفلوکساسین)؛ حساسیت.","Hepatic impairment (cirrhosis or active liver disease) or transaminases >3× ULN; potent CYP1A2 inhibitors (fluvoxamine, ciprofloxacin); hypersensitivity.",[66],{"source":33,"section":67},"4.3",[69],{"text":70,"refs":73},{"fa":71,"en":72},"آسیب کبدی (گاه نارسایی کبد)؛ پایش آزمایش کبد.","Liver injury (occasionally hepatic failure); monitor liver tests.",[74],{"source":33,"section":75},"4.4",[],[],[],{"status":80,"reviewer":81,"date":81},"unverified",null,[83],{"regimen":37,"formulation":22,"input":84,"expect":87},{"ageYears":85,"weightKg":86},40,70,{"perDose":27,"tabletsPerDoseRounded":5,"upperPerDose":47},[89],"N06AX22",{"status":91,"forms":92,"refs":97},"registered",[93],{"code":94,"en":95,"fa":96},"18949","AGOMELATINE 25 mg TABLET","قرص آگوملاتین ۲۵ میلی‌گرم",[98],{"source":99,"section":100,"url":101},"darooyab-generic","G-5431\u002FAgomelatine","https:\u002F\u002Fwww.darooyab.ir\u002FG-5431\u002FAgomelatine",[103,106,108],{"kind":104,"url":105,"label":89},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=N06AX22",{"kind":107,"url":101,"label":8},"darooyab",{"kind":109,"url":110,"label":111},"emc","https:\u002F\u002Fwww.medicines.org.uk\u002Femc\u002Fproduct\u002F6564\u002Fsmpc","eMC Valdoxan",{"pregnancy":113,"lactation":122,"pediatric":129,"geriatric":137},{"level":114,"text":115,"quote":118,"refs":119},"caution",{"fa":116,"en":117},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of agomelatine in pregnant women.",[120],{"source":33,"section":121},"4.6",{"level":114,"text":123,"quote":126,"refs":127},{"fa":124,"en":125},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Available pharmacodynamic\u002Ftoxicological data in animals have shown excretion of agomelatine\u002Fmetabolites in milk (see section 5.3).",[128],{"source":33,"section":121},{"level":130,"text":131,"quote":134,"refs":135},"not-established",{"fa":132,"en":133},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","Children and adolescents from 7 to 17 years The safety and efficacy of agomelatine in children and adolescents aged from 7 to 17 years for treatment of major depressive episodes have not been established.",[136],{"source":33,"section":50},{"level":138,"text":139,"quote":142,"refs":143},"ok",{"fa":140,"en":141},"برچسب: در سالمندان تفاوت یا تنظیم دوز خاصی ذکر نشده.","Label: no specific difference or dose adjustment stated for older adults.","No dose adjustment is required in relation to age (see section 5.2).",[144],{"source":33,"section":50},1792156160767]